Symposia: Gene Therapies
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Bleeding and Clotting, Biological therapies, Acute Myeloid Malignancies, AML, Fundamental Science, apoptosis, hemophilia, Translational Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Thalassemia, Combination therapy, Hemoglobinopathies, hematopoiesis, drug development, Diseases, Gene Therapy, Therapies, Immunotherapy, emerging technologies, Biological Processes, Myeloid Malignancies, Technology and Procedures, gene editing, molecular biology, Study Population, Transplantation, Animal model
Type: Oral
Hematology Disease Topics & Pathways:
Research, Bleeding and Clotting, Biological therapies, Acute Myeloid Malignancies, AML, Fundamental Science, apoptosis, hemophilia, Translational Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Thalassemia, Combination therapy, Hemoglobinopathies, hematopoiesis, drug development, Diseases, Gene Therapy, Therapies, Immunotherapy, emerging technologies, Biological Processes, Myeloid Malignancies, Technology and Procedures, gene editing, molecular biology, Study Population, Transplantation, Animal model
Saturday, December 10, 2022: 9:30 AM-11:00 AM
Great Hall BC
(Ernest N. Morial Convention Center)
Moderators:
Akshay Sharma, MBBS, St. Jude Children's Research Hospital
and
Catherine E. McGuinn, MD, Columbia University
Disclosures:
Sharma: Vertex Pharmaceuticals/CRISPR Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Clinical Trial Site PI; Novartis: Other: Clinical Trial Site PI; Magenta Therapeutics: Other: Clinical Trial Site PI; Spotlight Therapeutics: Consultancy; CRISPR Therapeutics: Other: Clinical Trial Site PI, Research Funding; Vindico Medical Education: Honoraria; Medexus Inc: Consultancy. McGuinn: BPL: Consultancy; CSL Berhing: Membership on an entity's Board of Directors or advisory committees; Genentech/ Roche: Membership on an entity's Board of Directors or advisory committees, Research Funding; HemaBiologics: Membership on an entity's Board of Directors or advisory committees; Octapharma: Membership on an entity's Board of Directors or advisory committees; Bayer: Membership on an entity's Board of Directors or advisory committees; Pfizer: Research Funding; Spark Therapeutics: Research Funding; Sanofi: Research Funding; Takeda: Research Funding.
9:30 AM
9:45 AM
10:00 AM
10:15 AM
10:45 AM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH